AbbVie’s SKYRIZI® Gains FDA Approval for Moderate to Severe Ulcerative Colitis and Crohn's Disease Following Successful Phase 3 Trials

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely ac...

June 20, 2024 | Thursday | News
Milestone Scientific Receives Regulatory Approval to Launch CompuFlo® Epidural System in Brazil

Milestone Scientific , a leading developer of computerized drug delivery instruments that provide painless and precise injections, announces that it has ...

June 19, 2024 | Wednesday | News
RevOpsis and Kemwell Partner to Accelerate Development of RO-104 for nAMD

Partnership to accelerate development of lead product candidate, RO-104; a first-in-class tri-specific biologic for treating neovascular age-relat...

June 18, 2024 | Tuesday | News
Alvotech and Advanz Pharma Partner to Commercialize Biosimilar Eylea® Candidates in Europe

  Alvotech  a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz P...

June 18, 2024 | Tuesday | News
Thermo Fisher Scientific's PPD Clinical Research Business Earns 13th Consecutive CRO Leadership Award

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, is embracing the theme of the 60th annual Drug ...

June 17, 2024 | Monday | News
AbbVie and FutureGen Announce Strategic Partnership to Develop Next-Generation IBD Therapy

AbbVie  and FutureGen Biopharmaceutical (Beijing) Co., Ltd. announced a license agreement to develop FG-M701, a next generation TL1A antibody for th...

June 14, 2024 | Friday | News
FDA Accepts Eisai and Biogen’s Application for Monthly Maintenance Dosing of Alzheimer's Drug LEQEMBI

Eisai Co.,  and Biogen announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Applicat...

June 10, 2024 | Monday | News
HUTCHMED (China) Initiates Phase I Clinical Trial of Menin Inhibitor HMPL-506 in Hematological Malignancies

HUTCHMED (China) announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in Ch...

June 07, 2024 | Friday | News
Bio-Thera's Biosimilar Bevacizumab Avzivi® Receives Positive CHMP Opinion, Moves Closer to European Approval

Bio-Thera Solutions , a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars,  announced th...

June 05, 2024 | Wednesday | News
FDA Launches START Program to Accelerate Rare Disease Drug Development

START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological p...

June 03, 2024 | Monday | News
MilliporeSigma Launches M-Trace® Software & Mobile App to Digitize Sterility Testing for Pharmaceutical Industry

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched its M...

May 29, 2024 | Wednesday | News
Helsinn Group and Angelini Pharma Renew Distribution Agreement for AULIN® and MESULID® in Eastern Europe

Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong ...

May 28, 2024 | Tuesday | News
FDA Grants Priority Review to Sarclisa for Transplant-Ineligible Multiple Myeloma Treatment

  Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review gran...

May 27, 2024 | Monday | News
Bristol Myers Squibb to Showcase Cutting-Edge Oncology and Hematology Advances at ASCO 2024 and EHA 2024

  Bristol Myers Squibb  announced its participation in the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the Eur...

May 24, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in